BNTX – BioNTech SE
BNTX — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
1.41
Margin Of Safety %
Put/Call OI Ratio
1.47
EPS Next Q Diff
-1.38
EPS Last/This Y
-3.53
EPS This/Next Y
0.31
Price
85.68
Target Price
133.77
Analyst Recom
1.57
Performance Q
-9.84
Upside
-179.4%
Beta
1.59
Ticker: BNTX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-02-27 | BNTX | 110.27 | 0.77 | 0.61 | 30376 |
| 2026-03-02 | BNTX | 107.48 | 0.77 | 1.68 | 30423 |
| 2026-03-03 | BNTX | 100.86 | 0.77 | 0.30 | 30569 |
| 2026-03-04 | BNTX | 103.8 | 0.75 | 1.08 | 31308 |
| 2026-03-05 | BNTX | 101.03 | 0.75 | 1.86 | 31346 |
| 2026-03-06 | BNTX | 101.55 | 0.75 | 0.88 | 31510 |
| 2026-03-09 | BNTX | 102.19 | 0.76 | 0.62 | 31602 |
| 2026-03-10 | BNTX | 83.97 | 0.75 | 1.86 | 31940 |
| 2026-03-11 | BNTX | 90.76 | 1.03 | 0.78 | 42700 |
| 2026-03-12 | BNTX | 90.05 | 1.06 | 2.78 | 44138 |
| 2026-03-13 | BNTX | 90.1 | 1.06 | 2.61 | 44138 |
| 2026-03-17 | BNTX | 94.89 | 1.13 | 0.59 | 46268 |
| 2026-03-18 | BNTX | 89.52 | 1.12 | 0.50 | 47680 |
| 2026-03-19 | BNTX | 89.31 | 1.09 | 3.20 | 47753 |
| 2026-03-20 | BNTX | 89.31 | 0.97 | 13.69 | 45383 |
| 2026-03-23 | BNTX | 88.44 | 1.50 | 0.24 | 38548 |
| 2026-03-24 | BNTX | 86.76 | 1.47 | 0.99 | 38938 |
| 2026-03-25 | BNTX | 88.85 | 1.47 | 1.10 | 38984 |
| 2026-03-26 | BNTX | 87.38 | 1.47 | 0.81 | 39396 |
| 2026-03-27 | BNTX | 85.65 | 1.47 | 1.10 | 39428 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-02-27 | BNTX | 110.39 | -108.0 | -1701.3 | -3.42 |
| 2026-03-02 | BNTX | 107.58 | -108.0 | -865.6 | -3.42 |
| 2026-03-03 | BNTX | 100.83 | -108.0 | -735.4 | -3.42 |
| 2026-03-04 | BNTX | 103.82 | -108.0 | -1020.4 | -3.42 |
| 2026-03-05 | BNTX | 101.95 | -108.0 | -842.6 | -3.42 |
| 2026-03-06 | BNTX | 101.55 | -108.0 | -888.0 | -3.42 |
| 2026-03-09 | BNTX | 102.31 | -108.0 | -1582.1 | -3.42 |
| 2026-03-10 | BNTX | 83.80 | -108.0 | -694.4 | -3.42 |
| 2026-03-11 | BNTX | 90.88 | -108.0 | -2341.2 | -3.42 |
| 2026-03-12 | BNTX | 90.03 | -24.7 | -1554.4 | -4.28 |
| 2026-03-13 | BNTX | 91.23 | -24.7 | -1600.3 | -4.28 |
| 2026-03-17 | BNTX | 94.85 | -22.0 | -1486.8 | -3.99 |
| 2026-03-18 | BNTX | 90.00 | -22.0 | -12.8 | -3.99 |
| 2026-03-19 | BNTX | 89.29 | -22.0 | -191.7 | -3.99 |
| 2026-03-20 | BNTX | 89.27 | -22.0 | -208.6 | -3.99 |
| 2026-03-23 | BNTX | 88.37 | -22.0 | -189.2 | -4.09 |
| 2026-03-24 | BNTX | 86.79 | -22.0 | -131.9 | -4.09 |
| 2026-03-25 | BNTX | 88.86 | -22.0 | -414.1 | -4.09 |
| 2026-03-26 | BNTX | 87.46 | -22.0 | -136.7 | -4.09 |
| 2026-03-27 | BNTX | 85.68 | -22.0 | -76.7 | -4.09 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-02-27 | BNTX | 0.00 | -5.75 | 1.97 |
| 2026-03-02 | BNTX | 0.00 | -1.59 | 1.97 |
| 2026-03-03 | BNTX | 0.00 | -1.59 | 1.97 |
| 2026-03-04 | BNTX | 0.00 | -1.59 | 1.97 |
| 2026-03-05 | BNTX | 0.00 | -1.59 | 1.97 |
| 2026-03-06 | BNTX | 0.00 | -1.59 | 1.97 |
| 2026-03-09 | BNTX | 0.00 | -1.60 | 1.97 |
| 2026-03-10 | BNTX | 0.00 | -1.60 | 1.97 |
| 2026-03-11 | BNTX | 0.00 | -1.60 | 1.86 |
| 2026-03-12 | BNTX | 0.00 | -1.60 | 1.78 |
| 2026-03-13 | BNTX | 0.00 | -1.60 | 1.78 |
| 2026-03-17 | BNTX | 0.00 | -1.53 | 1.78 |
| 2026-03-18 | BNTX | 0.00 | -1.53 | 1.78 |
| 2026-03-19 | BNTX | 0.00 | -1.53 | 1.78 |
| 2026-03-20 | BNTX | 0.00 | -1.53 | 1.78 |
| 2026-03-23 | BNTX | 0.00 | -1.51 | 1.78 |
| 2026-03-24 | BNTX | 0.00 | -1.51 | 1.78 |
| 2026-03-25 | BNTX | 0.00 | -1.51 | 1.41 |
| 2026-03-26 | BNTX | 0.00 | -1.51 | 1.41 |
| 2026-03-27 | BNTX | 0.00 | -1.51 | 1.41 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.38
Avg. EPS Est. Current Quarter
-2.11
Avg. EPS Est. Next Quarter
-1.76
Insider Transactions
Institutional Transactions
-1.51
Beta
1.59
Average Sales Estimate Current Quarter
155
Average Sales Estimate Next Quarter
175
Fair Value
Quality Score
54
Growth Score
38
Sentiment Score
39
Actual DrawDown %
81.5
Max Drawdown 5-Year %
-82.2
Target Price
133.77
P/E
Forward P/E
PEG
P/S
6.49
P/B
0.95
P/Free Cash Flow
67.67
EPS
-5.23
Average EPS Est. Cur. Y
-4.09
EPS Next Y. (Est.)
-3.78
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-38.09
Relative Volume
0.61
Return on Equity vs Sector %
-33.3
Return on Equity vs Industry %
-17
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
-1.86
EBIT Estimation
-76.7
◆
BNTX
Healthcare
$85.68
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
34.5
Range 1M
19.7%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
8.1%
EPS NY
0.3%
52W%
13.6%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+56.1% upside
Upside
+56.1%
Quality
54
BioNTech SESector: Healthcare
Industry: Biotechnology
Employees: 7807
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
BNTX
Latest News
—
Caricamento notizie per BNTX…
stock quote shares BNTX – BioNTech SE Stock Price stock today
news today BNTX – BioNTech SE stock forecast ,stock prediction 2023 2024 2025
marketwatch BNTX – BioNTech SE yahoo finance google finance
stock history BNTX – BioNTech SE invest stock market
stock prices BNTX premarket after hours
ticker BNTX fair value insiders trading